FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195853337> ?p ?o ?g. }

• W3195853337 endingPage "31" @default.
• W3195853337 startingPage "19" @default.
• W3195853337 abstract "A systematic review and meta-analysis were conducted, according to the PRISMA methodology, to summarize current evidence on the prevalence and predictors of long-term glucocorticoid (GC) treatment and disease relapses in the real-life management of polymyalgia rheumatica (PMR).Out of 5442 retrieved studies, 21 were eligible for meta-analysis and 24 for qualitative analysis. The pooled proportions of patients still taking GCs at 1, 2, and 5 years were respectively 77% (95%CI 71-83%), 51% (95%CI 41-61%), and 25% (95CI% 15-36%). No significant difference was recorded by distinguishing study cohorts recruited before and after the issue of the international recommendations in 2010. The pooled proportion of patients experiencing at least one relapse at 1 year from treatment initiation was 43% (95%CI 29-56%). Female gender, acute-phase reactants levels, peripheral arthritis, starting GCs dosage, and tapering speed were the most frequently investigated potential predictors of prolonged GC treatment and relapse, but with inconsistent results. Only a few studies and with conflicting results evaluated the potential role of early treatment with methotrexate in reducing the GC exposure and the risk of relapse in PMR.This study showed that a high rate of prolonged GC treatment is still recorded in the management of PMR. The relapse rate, even remarkable, can only partially explain the long-term GC treatment, suggesting that other and not yet identified factors may be involved. Additional research is needed to profile patients with a higher risk of long-term GC treatment and relapse and identify more effective steroid-sparing strategies. Key Points: • High rate of long-term glucocorticoid (GC) treatment is recorded in polymyalgia rheumatica (PMR), being 77%, 51%, and 25% of patients still on GCs after respectively 1, 2, and 5 years. • A pooled relapse rate of 43% at 1 year, even remarkable, can only partially explain the long-term GC treatment in PMR. • Several studies have attempted to identify potential predictors of prolonged treatment with GCs and relapse, but with inconsistent results. • Additional research is needed to profile patients with a higher risk of long-term GC treatment and relapse and identify more effective steroid-sparing strategies." @default.
• W3195853337 created "2021-08-30" @default.
• W3195853337 creator A5009025076 @default.
• W3195853337 creator A5009247038 @default.
• W3195853337 creator A5029683989 @default.
• W3195853337 creator A5030577320 @default.
• W3195853337 creator A5033305683 @default.
• W3195853337 creator A5049244075 @default.
• W3195853337 creator A5063394261 @default.
• W3195853337 creator A5075324483 @default.
• W3195853337 date "2021-08-20" @default.
• W3195853337 modified "2023-10-17" @default.
• W3195853337 title "Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis" @default.
• W3195853337 cites W190049262 @default.
• W3195853337 cites W1971672948 @default.
• W3195853337 cites W1983403395 @default.
• W3195853337 cites W1997377429 @default.
• W3195853337 cites W1999151514 @default.
• W3195853337 cites W2001331628 @default.
• W3195853337 cites W2004689666 @default.
• W3195853337 cites W2020229760 @default.
• W3195853337 cites W2025001196 @default.
• W3195853337 cites W2025125579 @default.
• W3195853337 cites W2050116365 @default.
• W3195853337 cites W2067809930 @default.
• W3195853337 cites W2084214906 @default.
• W3195853337 cites W2100651899 @default.
• W3195853337 cites W2101005100 @default.
• W3195853337 cites W2105611062 @default.
• W3195853337 cites W2111122944 @default.
• W3195853337 cites W2112224121 @default.
• W3195853337 cites W2115475246 @default.
• W3195853337 cites W2123969260 @default.
• W3195853337 cites W2125435699 @default.
• W3195853337 cites W2126269417 @default.
• W3195853337 cites W2128230480 @default.
• W3195853337 cites W2128783050 @default.
• W3195853337 cites W2139997704 @default.
• W3195853337 cites W2154610519 @default.
• W3195853337 cites W2157823046 @default.
• W3195853337 cites W2168788921 @default.
• W3195853337 cites W2169205464 @default.
• W3195853337 cites W2179482177 @default.
• W3195853337 cites W2179888812 @default.
• W3195853337 cites W2206140847 @default.
• W3195853337 cites W2288762703 @default.
• W3195853337 cites W2402729886 @default.
• W3195853337 cites W2418117904 @default.
• W3195853337 cites W2554354054 @default.
• W3195853337 cites W2564853619 @default.
• W3195853337 cites W2736027399 @default.
• W3195853337 cites W2742272122 @default.
• W3195853337 cites W2767898276 @default.
• W3195853337 cites W2805651945 @default.
• W3195853337 cites W2886569049 @default.
• W3195853337 cites W2899407851 @default.
• W3195853337 cites W2946418435 @default.
• W3195853337 cites W2961579158 @default.
• W3195853337 cites W2974663997 @default.
• W3195853337 cites W2991426373 @default.
• W3195853337 cites W3004448525 @default.
• W3195853337 cites W3005945513 @default.
• W3195853337 cites W3014493104 @default.
• W3195853337 cites W3029676562 @default.
• W3195853337 cites W3033931117 @default.
• W3195853337 cites W3045191822 @default.
• W3195853337 cites W3090608129 @default.
• W3195853337 cites W3093545047 @default.
• W3195853337 cites W4211106135 @default.
• W3195853337 doi "https://doi.org/10.1007/s10067-021-05819-z" @default.
• W3195853337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34415462" @default.
• W3195853337 hasPublicationYear "2021" @default.
• W3195853337 type Work @default.
• W3195853337 sameAs 3195853337 @default.
• W3195853337 citedByCount "22" @default.
• W3195853337 countsByYear W31958533372021 @default.
• W3195853337 countsByYear W31958533372022 @default.
• W3195853337 countsByYear W31958533372023 @default.
• W3195853337 crossrefType "journal-article" @default.
• W3195853337 hasAuthorship W3195853337A5009025076 @default.
• W3195853337 hasAuthorship W3195853337A5009247038 @default.
• W3195853337 hasAuthorship W3195853337A5029683989 @default.
• W3195853337 hasAuthorship W3195853337A5030577320 @default.
• W3195853337 hasAuthorship W3195853337A5033305683 @default.
• W3195853337 hasAuthorship W3195853337A5049244075 @default.
• W3195853337 hasAuthorship W3195853337A5063394261 @default.
• W3195853337 hasAuthorship W3195853337A5075324483 @default.
• W3195853337 hasBestOaLocation W31958533371 @default.
• W3195853337 hasConcept C126322002 @default.
• W3195853337 hasConcept C198451711 @default.
• W3195853337 hasConcept C2776015282 @default.
• W3195853337 hasConcept C2776712624 @default.
• W3195853337 hasConcept C2779134260 @default.
• W3195853337 hasConcept C2780079024 @default.
• W3195853337 hasConcept C2780841215 @default.
• W3195853337 hasConcept C71924100 @default.
• W3195853337 hasConcept C95190672 @default.
• W3195853337 hasConceptScore W3195853337C126322002 @default.

• next